Drugs / ADOPRAZINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00620568 | Feb → Mar 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00581243 | Jan → May 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADOPRAZINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL221692 ↗ |
| Known as | Adoprazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL221692 ↗ |
| Known as | SLV-313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00620568 ↗ |
| Action | Activate | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL221692 ↗ |
| Action | Inhibit | “Dopamine D2 receptor antagonist” CHEMBL221692 ↗1“Dopamine D3 receptor antagonist” CHEMBL221692 ↗ |
| Modality | Small molecule | — CHEMBL221692 ↗ |
| Route | Oral | “Administered Orally” NCT00581243 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL221692 ↗ |
| Target | DRD3 | “Dopamine D3 receptor antagonist” CHEMBL221692 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL221692 ↗ |